ACAD
30.37
-0.83
-2.66%
AEMD
0.21
-0.02
-6.67%
APRI
1.925
-0.005
-0.259%
ARNA
4.34
-0.02
-0.46%
ATEC
1.4
-0.04
-2.78%
CNAT
6.76
+1
+17.36%
CRXM
0.193
+0.00
+0.05714%
CYTX
1.18
-0.01
-0.84%
DXCM
58.37
-1.4
-2.34%
GNMK
13.09
+0.04
+0.31%
HALO
13.31
+0.02
+0.15%
ILMN
184.37
+1.09
+0.59%
INNV
0.149
-0.026
-14.6857%
INO
8.09
-0.1
-1.22%
ISCO
0.058
+0.00
+0.7005%
ISIS
61.15
-1.24
-1.99%
LGND
70.3
-0.4
-0.57%
LPTN
2.52
0.00
0.00%
MBVX
1.75
-0.32
-15.46%
MEIP
1.83
-0.07
-3.68%
MNOV
3.32
+0.04
+1.22%
MRTX
26.37
+0.65
+2.53%
MSTX
0.52
0.00
-0.19%
NBIX
37.33
+0.96
+2.64%
NUVA
43.98
-0.15
-0.34%
ONCS
0.339
-0.004
-1.0234%
ONVO
3.93
-0.1
-2.48%
OREX
7.25
+0.33
+4.77%
OTIC
33.76
+1.3
+4.00%
QDEL
26.52
-0.38
-1.41%
RCPT
138.99
+0.48
+0.35%
RGLS
16.56
+0.04
+0.24%
RMD
70.25
-0.13
-0.18%
SCIE
0.031
-0.004
-11.429%
SPHS
0.54
-0.02
-3.57%
SRNE
11.85
+0.07
+0.59%
TROV
6.77
+0.12
+1.80%
VICL
0.855
-0.009
-1.042%
VOLC
17.99
0.00
0.00%
ZGNX
1.31
+0.01
+0.77%
ACAD
30.37
-0.83
-2.66%
AEMD
0.21
-0.02
-6.67%
APRI
1.925
-0.005
-0.259%
ARNA
4.34
-0.02
-0.46%
ATEC
1.4
-0.04
-2.78%
CNAT
6.76
+1
+17.36%
CRXM
0.193
+0.00
+0.05714%
CYTX
1.18
-0.01
-0.84%
DXCM
58.37
-1.4
-2.34%
GNMK
13.09
+0.04
+0.31%
HALO
13.31
+0.02
+0.15%
ILMN
184.37
+1.09
+0.59%
INNV
0.149
-0.026
-14.6857%
INO
8.09
-0.1
-1.22%
ISCO
0.058
+0.00
+0.7005%
ISIS
61.15
-1.24
-1.99%
LGND
70.3
-0.4
-0.57%
LPTN
2.52
0.00
0.00%
MBVX
1.75
-0.32
-15.46%
MEIP
1.83
-0.07
-3.68%
MNOV
3.32
+0.04
+1.22%
MRTX
26.37
+0.65
+2.53%
MSTX
0.52
0.00
-0.19%
NBIX
37.33
+0.96
+2.64%
NUVA
43.98
-0.15
-0.34%
ONCS
0.339
-0.004
-1.0234%
ONVO
3.93
-0.1
-2.48%
OREX
7.25
+0.33
+4.77%
OTIC
33.76
+1.3
+4.00%
QDEL
26.52
-0.38
-1.41%
RCPT
138.99
+0.48
+0.35%
RGLS
16.56
+0.04
+0.24%
RMD
70.25
-0.13
-0.18%
SCIE
0.031
-0.004
-11.429%
SPHS
0.54
-0.02
-3.57%
SRNE
11.85
+0.07
+0.59%
TROV
6.77
+0.12
+1.80%
VICL
0.855
-0.009
-1.042%
VOLC
17.99
0.00
0.00%
ZGNX
1.31
+0.01
+0.77%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.